Nguyen Quang Hung, Dao Manh Phuong, Nguyen Thi Hoa Mai, Tran Thi Doan
Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam.
Oncology Center, Phenikaa University Hospital, Hanoi, Vietnam.
Cancer Manag Res. 2025 Aug 31;17:1851-1858. doi: 10.2147/CMAR.S537882. eCollection 2025.
To evaluate the efficacy of neoadjuvant therapy and identify associated factors influencing treatment response in patients with HER2-positive breast cancer.
A prospective, longitudinal study of 40 women with a mean age of 50.68 ± 10.53 years diagnosed with HER2-positive breast cancer. All patients received neoadjuvant treatment using Docetaxel-Carboplatin-Trastuzumab (TCH) regimens. These patients were evaluated for treatment response based on the Response Evaluation Criteria In Solid Tumors (RECIST) after six 21-day treatment cycles.
The proportion of good responders was 45.0% (18/40 patients). Younger age, earlier clinical stage, and lower baseline serum CA15-3 levels were significantly associated with a better response (p < 0.05). The incidence of adverse events was also significantly lower in good responders (p < 0.05). Multivariate analysis identified younger age and lower CA15-3 concentration as independent predictors of favorable response, with area under the Receiver Operating Characteristic (ROC) curves (AUC) of 0.758 and 0.821, respectively (p = 0.006 and p = 0.001).
Neoadjuvant treatment using the Docetaxel-Carboplatin-Trastuzumab regimen provides favorable clinical outcomes in HER2-positive breast cancer patients. Baseline CA15-3 levels may serve as a useful predictor of treatment response.
评估新辅助治疗的疗效，并确定影响HER2阳性乳腺癌患者治疗反应的相关因素。
对40例平均年龄为50.68±10.53岁的HER2阳性乳腺癌女性患者进行前瞻性纵向研究。所有患者均接受多西他赛-卡铂-曲妥珠单抗（TCH）方案的新辅助治疗。在六个21天的治疗周期后，根据实体瘤疗效评价标准（RECIST）对这些患者的治疗反应进行评估。
良好反应者的比例为45.0%（18/40例患者）。年龄较小、临床分期较早和基线血清CA15-3水平较低与较好的反应显著相关（p<0.05）。良好反应者的不良事件发生率也显著较低（p<0.05）。多因素分析确定年龄较小和CA15-3浓度较低是良好反应的独立预测因素，受试者工作特征（ROC）曲线下面积（AUC）分别为0.758和0.821（p=0.006和p=0.001）。
多西他赛-卡铂-曲妥珠单抗方案的新辅助治疗为HER2阳性乳腺癌患者提供了良好的临床疗效。基线CA15-3水平可能是治疗反应的有用预测指标。
